Filing Flows › Immunome (IMNM) › Q2 2025 › vs Q2 2024
Immunome (IMNM) Q2 2025 vs Q2 2024 (year over year)
Immunome's revenue rose $1.7M (+70%) from $2.4M in Q2 2024 to $4.0M in Q2 2025.
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart draws each line against Q2 2024, the increases inside each band.
Every line
| Line | Q2 2025 | Q2 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $4.0M | $2.4M | $1.7M | +70% |
| Other income, net | $3.1M | $3.9M | −$806K | -21% |
| Net loss | $43.4M | $36.1M | $7.3M | +20% |
| Costs & expenses | $50.5M | $42.4M | $8.1M | +19% |
| Operating costs | $50.5M | $42.4M | $8.1M | +19% |
| Research & development | $40.5M | $29.1M | $11.4M | +39% |
| General & admin | $10.0M | $7.0M | $3.1M | +44% |
| Operating cash sources | $55.4M | $27.2M | $28.2M | +104% |
| Depreciation & amortization | $637K | $549K | $88K | +16% |
| Share-based compensation | $5.3M | $3.2M | $2.1M | +66% |
| Cash used in operations | $49.4M | $23.4M | $26.0M | +111% |
| Net loss absorbed | $43.4M | $36.1M | $7.3M | +20% |
| Working capital & other | $12.0M | −$8.9M | $20.9M | — |
Questions
How much did Immunome's revenue grow year over year in Q2 2025?
Immunome's revenue rose $1.7M (+70%) from $2.4M in Q2 2024 to $4.0M in Q2 2025.